Successful Monitoring of Gaucher Disease

Treatment Efficiency in Gaucher Patients Can Reliably Be Monitored by Quantification of Lyso-Gb1 Concentrations in Dried Blood Spots

Biomarkers are key tools in establishing a diagnosis and monitoring rare disorders. The lipid metabolite Lyso-Gb1 has long been known as an excellent diagnostic biomarker. In a recent study, which was initiated and led by researchers at CENTOGENE, Lyso-Gb1 was shown to also be ideally suited for monitoring purposes. The findings were published in the International Journal of Molecular Sciences.

Author

  • Dr. rer. nat. Claudia Cozma , MD

Share